MedImmune and Mirati team up on durvalumab/mocetinostat for NSCLC
MedImmune, the global biologics R&D arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an exclusive clinical trial collaboration with oncology specialist Mirati Therapeutics (Nasdaq: MRTX).
The Phase I/II study will evaluate the safety and efficacy of MedImmune’s durvalumab, an investigational anti-PDL1 immune checkpoint inhibitor, in combination with mocetinostat, an investigational spectrum-selective histone deacetylase inhibitor from Mirati.
The combination will be evaluated in patients with non-small cell lung cancer (NSCLC) with the potential to explore additional indications in the future. Mirati will conduct and fund the initial Phase I/II clinical trial, expected to start in 2016, while MedImmune will supply durvalumab for the trial. Should the initial clinical trial demonstrate positive results, MedImmune will have an exclusive period of time in which to negotiate a commercial license for the combination in this indication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze